Alberto Larran-Alvarez
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 136 publications
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.
Journal: British journal of haematology
Published: May 14, 2026
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.
Journal: Blood cancer journal
Published: January 30, 2026
From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.
Journal: Annals of hematology
Published: January 21, 2026
Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.
Journal: American journal of hematology
Published: January 19, 2026
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.
Journal: Journal for immunotherapy of cancer
Published: November 25, 2025
Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.
Journal: The Journal of molecular diagnostics : JMD
Published: September 09, 2025
Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.
Journal: The Journal of molecular diagnostics : JMD
Published: September 09, 2025
Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.
Journal: JHEP reports : innovation in hepatology
Published: August 18, 2025
Last Updated: 09/26/2026